REPORT: Pharma steps up M&A, but specialty companies dominate
This article was originally published in Scrip
Executive Summary
Biopharmaceutical mergers and acquisitions more than doubled from $75bn in 2013 to $220bn in 2014 and big pharma played a larger role with $90bn in transactions last year aimed at boosting dwindling sales growth, but specialty pharmaceutical companies outspent their larger counterparts with $130bn in M&A deals with the goal of building portfolios that can compete on a global scale.
You may also be interested in...
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.